Source study found
Story checked
New CRISPR approach targets gene fusions found in 1 in 5 cancers (opens in a new tab)
medicalxpress.com · 2026-10-19
Short answer
Mostly not supportedMostly not supported.
2 claims go further than the study. 2 other points were not covered by the paper.
- 1 supported
- 2 overstated
- 2 not covered
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
New CRISPR approach targets gene fusions found in 1 in 5 cancers
medicalxpress.com · 2026-10-19
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Mostly not supported
Two of five claims overstate the study. One of five checks out. Two claims the study doesn't address.
- 1 supported
- 2 overstated
- 2 not covered
The source study
Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition
Evidence layer
Claim by claim
Each claim gets a verdict. Expand it to see the evidence directly below.
Reading mode
Scan verdicts. Open evidence only when needed.
Browse by verdict
5 claims in this storyShowing all 5 claimsChoose a verdict to focus the list.
Claim 1 of 5OverstatedPeter Mac scientists have developed a way to precisely target the 'unique molecular fingerprint' created when two genes become abnormally fused together, which the article says could lead to a new way to treat a wide array of cancers.View evidenceHide evidence
As stateda wide array of cancers
Why this verdict
The abstract-level profile supports a programmable PspCas13b strategy that recognizes fusion breakpoint sequences and silences fusion transcripts, with broader personalization beyond BCR::ABL1. However, the headline-level framing that this could become a treatment for a “wide array of cancers” goes beyond the in-vitro proof-of-concept evidence supplied. The body caveats about cell models and no animal/human testing temper the story, but the headline still outruns the demonstrated evidence.
Study evidence
PspCas13b programmed to recognize the fusion breakpoint cleaves and disrupts the fusion transcript, resulting in efficient depletion of the encoded fusion protein.
“We reveal that recognition and cleavage of the breakpoint sequence by PspCas13b disrupt the fusion transcript, resulting in efficient protein depletion.”
Study evidence
Personalized PspCas13b guides that target fusion-specific breakpoint sequences effectively silence multiple other oncogenic fusion transcripts beyond BCR::ABL1.
“Beyond BCR::ABL1, personalized design of PspCas13b effectively silences other undruggable oncogenic fusions.”
Claim 2 of 5OverstatedIn the paper, Fareh, along with Dr. Wenxin Hu and colleagues, describes a novel method using CRISPR-Cas13 that can be programmed to recognize the fusion breakpoint and silence gene fusions, stopping their downstream cancer-driving effects.View evidenceHide evidence
As statednine different gene fusions
Why this verdict
The core method is supported: PspCas13b can be programmed to recognize breakpoint sequences, cleave/disrupt fusion transcripts, and deplete fusion protein. The BCR::ABL1 model also supports downstream molecular and phenotypic effects. But the story’s broader phrasing that silencing gene fusions stops downstream cancer-driving effects, together with the stated magnitude of nine fusions, is stronger than the abstract-level profile supports: downstream functional consequences are detailed mainly for BCR::ABL1, while the number and identities of additional fusions are not provided at this depth.
Study evidence
PspCas13b programmed to recognize the fusion breakpoint cleaves and disrupts the fusion transcript, resulting in efficient depletion of the encoded fusion protein.
“We reveal that recognition and cleavage of the breakpoint sequence by PspCas13b disrupt the fusion transcript, resulting in efficient protein depletion.”
Study evidence
PspCas13b targeting the BCR::ABL1 breakpoint efficiently degrades both wild-type and drug-resistant BCR::ABL1 transcripts.
“We demonstrate that targeting the BCR::ABL1 breakpoint sequence efficiently degrades both wild-type and drug-resistant BCR::ABL1 mutants...”
Claim 3 of 5Not coveredThe article says gene fusions are present in about 20% of all cancers and are 'bona fide oncogenic drivers' for 16.5% of all cancers.View evidenceHide evidence
As statedabout 20% of all cancers; 16.5% of all cancers
Why this verdict
The supplied abstract-level profile supports the general idea that oncogenic gene fusions are important cancer drivers, but it does not provide the quoted epidemiologic figures of about 20% of all cancers or 16.5% as bona fide oncogenic drivers. Those exact prevalence/magnitude claims are not verifiable from the abstract-profile evidence.
Study evidence
PspCas13b programmed to recognize the fusion breakpoint cleaves and disrupts the fusion transcript, resulting in efficient depletion of the encoded fusion protein.
“We reveal that recognition and cleavage of the breakpoint sequence by PspCas13b disrupt the fusion transcript, resulting in efficient protein depletion.”
Claim 4 of 5Not coveredBCR-ABL1 was among nine different gene fusions that were successfully targeted and silenced in this proof-of-concept research.View evidenceHide evidence
As statednine different gene fusions
Why this verdict
The profile supports that BCR::ABL1 was successfully targeted/silenced and that additional oncogenic fusions beyond BCR::ABL1 were silenced. However, the abstract-level evidence does not specify that there were exactly nine different gene fusions, so the claim as quantified is not verifiable at the requested evidence depth.
Study evidence
PspCas13b targeting the BCR::ABL1 breakpoint efficiently degrades both wild-type and drug-resistant BCR::ABL1 transcripts.
“We demonstrate that targeting the BCR::ABL1 breakpoint sequence efficiently degrades both wild-type and drug-resistant BCR::ABL1 mutants...”
Study evidence
Personalized PspCas13b guides that target fusion-specific breakpoint sequences effectively silence multiple other oncogenic fusion transcripts beyond BCR::ABL1.
“Beyond BCR::ABL1, personalized design of PspCas13b effectively silences other undruggable oncogenic fusions.”
Claim 5 of 5SupportedThe method has so far been demonstrated in laboratory cell models and has not yet been tested in animals or people; the next step is to determine delivery to tumors in the body and whether it can selectively target cancer cells in more complex models.View evidenceHide evidence
Why this verdict
The paper profile consistently describes the evidence as in-vitro/cell-model work and notes that in-vivo and clinical applicability are not addressed in the abstract. The story’s caveats that the work has not yet been tested in animals or people and that delivery to tumors remains unresolved are aligned with these limitations, although the exact phrasing of “next step” is not independently established in the supplied abstract profile.
Study evidence
PspCas13b programmed to recognize the fusion breakpoint cleaves and disrupts the fusion transcript, resulting in efficient depletion of the encoded fusion protein.
“We reveal that recognition and cleavage of the breakpoint sequence by PspCas13b disrupt the fusion transcript, resulting in efficient protein depletion.”
Study evidence
PspCas13b targeting the BCR::ABL1 breakpoint efficiently degrades both wild-type and drug-resistant BCR::ABL1 transcripts.
“We demonstrate that targeting the BCR::ABL1 breakpoint sequence efficiently degrades both wild-type and drug-resistant BCR::ABL1 mutants...”
Context layer
What the story left out
Important study details the story did not include.
PspCas13b cleavage produces aberrant, translation-incompetent RNA species, including some internal deletions near the cleavage site.
The story conveys silencing but does not mention this mechanistic characterization of the RNA cleavage products, which is a primary mechanistic element in the abstract profile.
From in_vitro CRISPR-PspCas13b breakpoint-targeting assays
4 things the story did carry across
- PspCas13b can be programmed with guide RNAs recognizing fusion breakpoint sequences to cleave/disrupt fusion transcripts and deplete fusion protein.
- Targeting BCR::ABL1 in CML cell models degrades wild-type and drug-resistant BCR::ABL1, impairs kinase activity, remodels transcriptomic/proteomic states, and leads to erythroid differentiation and apoptosis in drug-resistant cells.
- The platform was reported to silence additional oncogenic fusion transcripts beyond BCR::ABL1, supporting personalization/generalizability.
- The evidence in the supplied profile is in vitro/cell-model proof of concept, with no in-vivo or clinical validation addressed.
Study layer
Study at a glance
Scan the study first. Expand only the parts you want to inspect.
Pieces of work
3
Evidence read
study summary
Lead result
in vitro
1Lead resultin vitroEstablish CRISPR-PspCas13b breakpoint-sequence recognition as a programmable strategy to selectively cleave/silence oncogenic fusion transcripts, yielding efficient fusion-protein depletion and characteristic aberrant RNA products.in vitro CRISPR-PspCas13b breakpoint-targeting assaysExpandCollapse
In plain English
The study establishes that PspCas13b programmed with guide RNAs that recognize fusion breakpoint sequences cleaves the fusion transcript at/near the breakpoint, disrupting the transcript and producing loss of fusion protein. Cleavage yields aberrant, translation-incompetent RNA species, including a subset with internal deletions proximal to the cleavage site.
Key findings
- PspCas13b programmed to recognize the fusion breakpoint cleaves and disrupts the fusion transcript, resulting in efficient depletion of the encoded fusion protein.
- PspCas13b cleavage of the target fusion transcript produces aberrant, translation-incompetent RNA species; some cleavage products contain internal deletions near the cleavage site.
“We reveal that recognition and cleavage of the breakpoint sequence by PspCas13b disrupt the fusion transcript, resulting in efficient protein depletion.”
What this piece can’t prove
3 further details could not be confirmed from the summary.
2in vitroDemonstrate functional and molecular consequences of targeting the BCR::ABL1 breakpoint in (including drug-resistant) CML model cells: kinase impairment, broad transcriptomic/proteomic remodeling, erythroid differentiation, and apoptosis.in vitro CML cell modelsExpandCollapse
In plain English
In CML cell models, PspCas13b programmed to recognize the BCR::ABL1 breakpoint degrades both wild-type and drug-resistant BCR::ABL1 transcripts, reduces BCR::ABL1 tyrosine phosphokinase activity, induces broad transcriptomic and proteomic remodeling, and drives erythroid differentiation and apoptosis in drug-resistant cells.
Key findings
- PspCas13b targeting the BCR::ABL1 breakpoint efficiently degrades both wild-type and drug-resistant BCR::ABL1 transcripts.
- Targeting BCR::ABL1 with PspCas13b impairs BCR::ABL1 tyrosine phosphokinase activity.
“We demonstrate that targeting the BCR::ABL1 breakpoint sequence efficiently degrades both wild-type and drug-resistant BCR::ABL1 mutants...”
What this piece can’t prove
3 further details could not be confirmed from the summary.
3in vitroShow generalizability/personalizability beyond BCR::ABL1 by designing breakpoint-targeting PspCas13b guides that silence additional undruggable oncogenic fusion transcripts.in vitroExpandCollapse
In plain English
The authors report that personalized PspCas13b guides targeting fusion breakpoint sequences can be designed to silence additional oncogenic fusion transcripts beyond BCR::ABL1, indicating platform generalizability across multiple undruggable fusion targets.
Key findings
- Personalized PspCas13b guides that target fusion-specific breakpoint sequences effectively silence multiple other oncogenic fusion transcripts beyond BCR::ABL1.
“Beyond BCR::ABL1, personalized design of PspCas13b effectively silences other undruggable oncogenic fusions.”
What this piece can’t prove
3 further details could not be confirmed from the summary.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition
Science advances · 2026
Why this one
Near certain
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
PubMed, Europe PMC, Crossref · 37 candidate papers
Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition
Science Advances · 2026 · PubMed, Europe PMC, Crossref
Author response for "Advances in light-independent copper-based nanomaterials for antibacterial applications"
2026 · Crossref
[Immunocyte energy metabolism imbalance and precision treatment in vitiligo: Mechanistic insights and advances in targeted intervention].
2026 · Europe PMC
Comprehensive characterization of transposable element expression reveals regulatory circuitry and clinical implications in cancers.
Science Advances · 2026 · PubMed
Author response for "MXene Composites for Multimodal Detection of Food Contaminants: Advances and Future Outlook"
2026 · Crossref
Synthesis of 6,7-dihydrobenzo[d]oxazol-4(5H)-ones through cascade N-H insertion and intramolecular annulation of cyclic 2-diazo-1,3-diketones with amides.
2026 · Europe PMC
And 31 more candidates considered.